Peter T Beernink
Overview
Explore the profile of Peter T Beernink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raghunathan D, Lim S, Moe G, Beernink P
Infect Immun
. 2025 Feb;
93(3):e0033924.
PMID: 39992115
Neisserial surface protein A (NspA) is a small, conserved outer membrane protein that has been investigated as a vaccine antigen against meningococcal disease. After NspA had been tested in humans,...
2.
Beernink P, Di Carluccio C, Marchetti R, Cerofolini L, Carillo S, Cangiano A, et al.
JACS Au
. 2024 Jul;
4(7):2617-2629.
PMID: 39055159
The spread of multidrug-resistant strains of , the etiologic agent of gonorrhea, represents a global health emergency. Therefore, the development of a safe and effective vaccine against gonorrhea is urgently...
3.
An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
Dold C, Marsay L, Wang N, Silva-Reyes L, Clutterbuck E, Paterson G, et al.
Sci Transl Med
. 2023 Jun;
15(701):eade3901.
PMID: 37343082
Adenoviral-vectored vaccines are licensed for prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ebola virus, but, for bacterial proteins, expression in a eukaryotic cell may affect the antigen's...
4.
Sands N, Beernink P
PLoS Pathog
. 2021 Jun;
17(6):e1009655.
PMID: 34125873
Microbial pathogens bind host complement regulatory proteins to evade the immune system. The bacterial pathogen Neisseria meningitidis, or meningococcus, binds several complement regulators, including human Factor H (FH). FH binding...
5.
Findlow J, Bayliss C, Beernink P, Borrow R, Liberator P, Balmer P
Vaccine
. 2020 Sep;
38(49):7716-7727.
PMID: 32878710
Neisseria meningitidis, the causative agent of invasive meningococcal disease (IMD), is classified into different serogroups defined by their polysaccharide capsules. Meningococcal serogroups A, B, C, W, and Y are responsible...
6.
Beernink P
Hum Vaccin Immunother
. 2019 Sep;
16(3):703-712.
PMID: 31526219
Bacteria produce surface ligands for host complement regulators including Factor H (FH), which allows the bacteria to evade immunity. Meningococcal Factor H binding protein (FHbp) is both a virulence factor...
7.
Sharkey K, Beernink P, Langley J, Gantt S, Quach C, Dold C, et al.
mSphere
. 2019 Jul;
4(4).
PMID: 31270173
Meningococcal serogroup B (MenB) vaccines contain recombinant factor H binding protein (FHbp), which can complex with complement factor H (CFH) and thereby risk eliciting anti-FH autoantibodies. While anti-FH antibodies can...
8.
Beernink P, Vianzon V, Lewis L, Moe G, Granoff D
mBio
. 2019 Jun;
10(3).
PMID: 31213564
MenB-4C (Bexsero; GlaxoSmithKline Biologicals) is a licensed meningococcal vaccine for capsular B strains. The vaccine contains detergent-extracted outer membrane vesicles (dOMV) and three recombinant proteins, of which one is factor...
9.
Beernink P, Ispasanie E, Lewis L, Ram S, Moe G, Granoff D
J Infect Dis
. 2018 Oct;
219(7):1130-1137.
PMID: 30346576
Background: Meningococcal outer membrane vesicle (OMV) vaccines are prepared with detergents to remove endotoxin, which also remove desirable antigens such as factor H binding protein (FHbp). Native OMV (NOMV) vaccines...
10.
Beernink P, Krupka S, Lao V, Martin G, Coleman M
ScientificWorldJournal
. 2018 Jul;
2:73-74.
PMID: 29973809
No abstract available.